| Name | Title | Contact Details |
|---|
Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.
PDI Ninth House is a Minneapolis, MN-based company in the Business Services sector.
TriLink BioTechnologies, part of Maravai LifeSciences, is a prominent contract development and manufacturing organization (CDMO) based in San Diego. Founded in 1996, the company specializes in the synthesis of nucleic acids, nucleoside triphosphates (NTPs), and mRNA capping analogs. TriLink provides advanced scale-up expertise and unique production capabilities for mRNA, oligonucleotides, and plasmids, catering to clients in therapeutics, vaccines, diagnostics, and biopharmaceutical innovations. The company offers custom synthesis and manufacturing services, supporting clients from early research through clinical trials. TriLinks proprietary CleanCap® technology enhances mRNA manufacturing efficiency, resulting in improved yields. Their product portfolio includes custom and modified oligonucleotides, plasmids, mRNA, and CleanCap® reagents. TriLink adheres to stringent quality systems compliant with ICH Q7, GMP guidelines, and ISO 9001:2015 standards, ensuring high-quality manufacturing for a diverse range of applications. The company collaborates with various organizations, including the U.S. Department of Defense, to support the development of critical mRNA vaccines and therapeutics.
Monarch Steel is a steel product provider that specializes in hot rolled, cold rolled, and galvanized steel. They have a customer-centric approach and strive to help their customers achieve their steel sourcing goals.
AMK INC is a Tulsa, OK-based company in the Business Services sector.